Search results
Results from the WOW.Com Content Network
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
Shares of Halozyme have been sliced in half after hours, wiping out more than $450 million in value. This is what happens when a binary event goes bad. The following video has all the gory details ...
What: Shares of Halozyme Therapeutics climbed as. Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they ...
Halozyme Therapeutics, Inc. (NASDAQ:HALO) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:EVO) for 11 euro ($11.44) per share ...
For premium support please call: 800-290-4726 more ways to reach us
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Halozyme Therapeutics Inc (NASDAQ:HALO), with a market capitalization of US$2.2b, rarely draw their ...
For premium support please call: 800-290-4726 more ways to reach us
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.